Home › Research › Drug development
Low Dose Lithium Treatment of Behavioral Complications in Alzheimer's Disease: Lit-AD Randomized Clinical Trial
D P Devanand, Elizabeth Crocco, Brent P Forester, Mustafa M Husain, Seonjoo Lee, Ipsit V Vahia, Howard Andrews, Laura Simon-Pearson et al.. The American journal of geriatric psychiatry : official journal of the American Association for Geriatric Psychiatry, 2021-05-12
Topic: Drug trials: efficacy and safety
Plain-language summary
Fifty-eight of 77 patients (75.3%) completed the trial. In linear mixed effects model analyses, lithium was not significantly superior to placebo for agitation/aggression. Proportion of responders was 31.6% on lithium and 17.9% on placebo (χ2=1.26, p = 0.26). Moderate or marked improvement (CGI) was greater on lithium (10/38=36.8%) than placebo (0/39=0%, Fisher's exact test p <0.001). In exploratory analyses, improvement on lithium was greater than placebo on NPI delusions and irritability/lability (p's<0.05). Lithium showed greater reduction than placebo in patients with high Young Mania Rating Scale scores (β=5.06; 95%CI,1.18 to 8.94, p = 0.01). Oral dose and serum levels demonstrated similar associations with efficacy outcomes. Lithium did not differ significantly from placebo on safety outcomes. Low-dose lithium was not efficacious in treating agitation but was associated with global clinical improvement and excellent safety. A larger trial may be warranted of likely lithium-responsive behavioral symptoms that overlap with mania.
Cite this study APA, Vancouver, BibTeX · download .bib or .ris
APA 7th
Devanand, D. P., Crocco, E., Forester, B. P., Husain, M. M., Lee, S., Vahia, I. V., et al. (2022). Low Dose Lithium Treatment of Behavioral Complications in Alzheimer's Disease: Lit-AD Randomized Clinical Trial. The American journal of geriatric psychiatry : official journal of the American Association for Geriatric Psychiatry. https://doi.org/10.1016/j.jagp.2021.04.014
Vancouver
Devanand DP, Crocco E, Forester BP, Husain MM, Lee S, Vahia IV, et al. Low Dose Lithium Treatment of Behavioral Complications in Alzheimer's Disease: Lit-AD Randomized Clinical Trial. The American journal of geriatric psychiatry : official journal of the American Association for Geriatric Psychiatry. 2022. doi:10.1016/j.jagp.2021.04.014. PMID: 34059401.
BibTeX
@article{devanand2022-34059401,
author = {Devanand, D P and Crocco, Elizabeth and Forester, Brent P and Husain, Mustafa M and Lee, Seonjoo and Vahia, Ipsit V and Andrews, Howard and Simon-Pearson, Laura and others},
title = {{Low Dose Lithium Treatment of Behavioral Complications in Alzheimer's Disease: Lit-AD Randomized Clinical Trial}},
journal = {The American journal of geriatric psychiatry : official journal of the American Association for Geriatric Psychiatry},
year = {2022},
doi = {10.1016/j.jagp.2021.04.014},
pmid = {34059401},
url = {https://doi.org/10.1016/j.jagp.2021.04.014}
}
Built from the record alzhub holds for this paper, not looked up. Volume, issue and page numbers are not held in the record. The record's author list ends in “et al.”, so not every author is named. Check the citation against the original before you use it.
Key findings
- Fifty-eight of 77 patients (75.3%) completed the trial.
- In linear mixed effects model analyses, lithium was not significantly superior to placebo for agitation/aggression.
- Proportion of responders was 31.6% on lithium and 17.9% on placebo (χ2=1.26, p = 0.26).
- Moderate or marked improvement (CGI) was greater on lithium (10/38=36.8%) than placebo (0/39=0%, Fisher's exact test p <0.001).
- In exploratory analyses, improvement on lithium was greater than placebo on NPI delusions and irritability/lability (p's<0.05).
New to this subject? Start with our plain-English guide: Treatments →
Study details
- Participants77
- Effect size75.3%; 31.6%; 17.9%
- Evidence strengthHigh
How this study scored 80/100
Published in a peer-reviewed journal, and it is a randomized controlled trial. We have no data on journal's citation record, times cited, citations per year, impact for its field and year, cited by studies here, still being cited, senior author's track record, institution's track record, multicenter collaboration and free to read, so those were left out: it earned 45 of the 56 points we could judge it on, which is 80 out of 100.
| Component | Points | Why |
|---|---|---|
| Journal tier | 7 / 10 | Tier 3 — peer-reviewed journal (The American journal of geriatric psychiatry : official journal of the American Association for Geriatric Psychiatry) |
| Journal's citation record | — / 4 | No journal record from OpenAlex — left out of this score |
| Study design | 11 / 12 | A randomized controlled trial (from PubMed type “Randomized Controlled Trial”) |
| Strength of evidence | 5 / 5 | Rated “high” in our summary |
| Peer-review validation | 10 / 10 | Peer-reviewed. Published as an article in a named peer-reviewed journal. |
| How recent | 3 / 5 | 2022 — within 6 year(s) of the newest study here |
| Sample size | 1 / 4 | 77 participants |
| Effect reported | 2 / 3 | Effect reported as a number, without an interval or test |
| Studied in people | 3 / 3 | Studied in people (participant count stated) |
| Randomized / blinded | 1 / 2 | Randomized (as stated in the record) |
| Times cited | — / 7 | No citation count (not found in OpenAlex) — left out of this score |
| Citations per year | — / 5 | No citation count or no year — left out of this score |
| Impact for its field and year | — / 6 | No field-weighted citation impact (OpenAlex has none yet) — left out of this score |
| Cited by studies here | — / 6 | Not yet checked against this library's citation graph — left out of this score |
| Still being cited | — / 4 | No yearly citation counts — left out of this score |
| Senior author's track record | — / 4 | Senior author's record not available — left out of this score |
| Institution's track record | — / 3 | No institution listed in OpenAlex — left out of this score |
| Multicenter collaboration | — / 3 | Institutions not listed — left out of this score |
| Indexed in PubMed | 2 / 2 | Indexed in PubMed (PMID 34059401) |
| Free to read | — / 2 | Access not recorded — left out of this score |
| Points | 45 / 56 | Scored on 10 of 20 parts. We have no data for the rest, so they are left out: 45 of the 56 points we could judge it on is 80 out of 100. |
| Total | 80 / 100 | — |
What each of these 20 components measures, and what this score is not →
Read the original
Free copy unknown: no free-copy check has an answer for this record yet. That does not mean it is paywalled.
Related
Studies in the library that share something with this one. The line above each title says what.
Related studies in Drug development from nearby years
Also tagged “late-life-depression”
139 studies in the library carry the topic tag “late-life-depression”; these are this study's neighbours in a fixed, alphabetical-by-hash tour of them, not the closest in content. All 139 tagged studies.